Development and Validation of a Next-Generation Sequencing Panel for Syndromic and Nonsyndromic Hearing Loss

被引:1
|
作者
Butz, Malinda [1 ]
McDonald, Amber [1 ]
Lundquist, Patrick A. [1 ]
Meyer, Melanie [1 ]
Harrington, Sean [1 ]
Kester, Sarah [1 ]
Stein, Mariam, I [2 ]
Mistry, Nipun A. [2 ]
Zuckerman, Eric Zimmerman [3 ]
Niu, Zhiyv [1 ,3 ,4 ]
Schimmenti, Lisa [4 ,5 ,6 ]
Hasadsri, Linda [1 ]
Boczeka, Nicole J. [1 ,4 ]
机构
[1] Mayo Clin, Genom Lab, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Lab Med & Pathol, Clin Genome Sequencing Lab, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Clin Genom, Mayo 19,200 First St SW, Rochester, MN 55905 USA
[5] Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN 55905 USA
[6] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
来源
关键词
MEDICAL GENETICS; AMERICAN-COLLEGE; GUIDELINES; GENOMICS;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Deafness and hearing loss are common conditions that can be seen independently or as part of a syndrome and are often mediated by genetic causes. We sought to develop and validate a hereditary hearing loss panel (HHLP) to detect single nucleotide variants (SNVs), insertions and deletions (indels), and copy number variants (CNVs) in 166 genes related to nonsyndromic and syndromic hearing loss. Methods: We developed a custom-capture next-generation sequencing (NGS) reagent to detect all coding regions, 610 flanking bp, for the 166 genes related to nonsyndromic and syndromic hearing loss. Our validation consisted of testing 52 samples to establish accuracy, reproducibility, and analytical sensitivity. In addition to NGS, supplementary methods, including multiplex ligation-dependent probe amplification, long-range PCR, and Sanger sequencing, were used to ensure coverage of regions that had high complexity or homology. Results: We observed 100% positive and negative percentage agreement for detection of SNVs (n = 362), small indels (1-22 bp, n = 25), and CNVs (gains, n = 8; losses, n = 17). Finally, we showed that this assay was able to detect variants with a variant allele frequency >= 20% for SNVs and indels and >= 30% to 35% for CNVs. Conclusions: We validated an HHLP that detects SNVs, indels, and CNVs in 166 genes related to syndromic and nonsyndromic hearing loss. The results of this assay can be utilized to confirm a diagnosis of hearing loss and related syndromic disorders associated with known causal genes.
引用
收藏
页码:467 / 479
页数:13
相关论文
共 50 条
  • [31] Targeted Next-Generation Sequencing (NGS) gene panel testing in 200 Danish individuals with primary non-syndromic hearing impairment
    Rendtorff, N. D.
    Karstensen, H. G.
    Hindbaek, L. S.
    Tranebjaerg, L.
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1224 - 1225
  • [32] TECHNICAL VALIDATION OF A NEXT-GENERATION SEQUENCING PANEL FOR ACUTE MYELOID LEUKEMIA DIAGNOSIS
    Llop, M.
    Alonso, C. M.
    Ibanez, M.
    Cervera, J.
    Such, E.
    Pedrola, L.
    Martin, I.
    Onecha, E.
    Ayala, R.
    Sanz, M. A.
    Barragan, E.
    [J]. HAEMATOLOGICA, 2016, 101 : 665 - 665
  • [33] Validation of a next-generation sequencing oncology panel optimized for low input DNA
    Sussman, Robyn T.
    Shaffer, Sydney
    Azzato, Elizabeth M.
    DeSloover, Daniel
    Farooqi, Midhat S.
    Meyer, Anders
    Lieberman, David B.
    Bigdeli, Ashkan
    Paolillo, Carmela
    Ganapathy, Karthik
    Sukhadia, Shrey
    Rosenbaum, Jason N.
    Daber, Robert D.
    Morrissette, Jennifer J. D.
    [J]. CANCER GENETICS, 2018, 228 : 55 - 63
  • [34] Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
    Hannah L. Williams
    Kathy Walsh
    Austin Diamond
    Anca Oniscu
    Zandra C. Deans
    [J]. Virchows Archiv, 2018, 473 : 489 - 503
  • [35] Validation of a Targeted Next-Generation Sequencing Panel to Screen for Mutations in Myeloid Leukemia
    Yang, F.
    Beadling, C.
    Neff, T. L.
    Dunlap, J.
    Corless, C. L.
    Press, R.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 864 - 865
  • [36] Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
    Williams, Hannah L.
    Walsh, Kathy
    Diamond, Austin
    Oniscu, Anca
    Deans, Zandra C.
    [J]. VIRCHOWS ARCHIV, 2018, 473 (04) : 489 - 503
  • [37] Development and Validation of a Pan-solid Tumor Next-Generation Sequencing Panel with a Customized Bioinformatics Pipeline
    Yin, L.
    Brock, J. E.
    Tu, Z. J.
    Cheng, Y.
    Weindel, M.
    Farkas, D. H.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1202 - 1202
  • [38] Interpretation of next-generation sequencing results targeting pediatric sensorineural hearing loss
    Clay, S. M.
    Evans, A.
    Hicks, C.
    Tsien, F.
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 365 : S276 - S276
  • [39] Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing
    Rosenthal, Sun Hee
    Sun, Weimin
    Zhang, Ke
    Liu, Yan
    Nguyen, Quoclinh
    Gerasimova, Anna
    Nery, Camille
    Cheng, Linda
    Castonguay, Carolyn
    Hiller, Elaine
    Li, James
    Elzinga, Christopher
    Wolfson, David
    Smolgovsky, Alla
    Chen, Rebecca
    Buller-Burckle, Arlene
    Catanese, Joseph
    Grupe, Andrew
    Lacbawan, Felicitas
    Owen, Renius
    [J]. BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [40] Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy
    Wang, Dandan
    Ma, Kai
    Deng, Wei
    Li, Jingyu
    Xiang, Shaohua
    Zhang, Yang
    Fu, Ying
    Dai, Heng
    Huang, Bingding
    [J]. ONCOTARGETS AND THERAPY, 2021, 14 : 2423 - 2431